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Chemical Genetic Screening Identifies Tricyclic
Compounds that Decrease Cellular Melanin Content
Li Ni-Komatsu1,2 and Seth J. Orlow1,2
A screen of a library of 2,000 drugs and natural products in murine melanocytes identified 10 tricyclic
antidepressants (TCAs) as compounds that potently decreased intracellular melanin content. The rank order of
potency of these compounds for decreasing melanin content was different than their relative potencies as
antidepressants. These compounds had no effect on either the level or the enzymatic activity of cellular
tyrosinase (Tyr). Increased presence of both Tyr and melanin in the culture media was observed in treated
melanocytes. Immunofluorescence localization revealed that these compounds decreased intracellular melanin
content by disrupting the intracellular trafficking of Tyr gene family proteins. In treated melanocytes, Tyr, Tyr-
related protein 1, and dopachrome tautomerase accumulated in enlarged granules distributed throughout the
cytoplasm. Colocalization of Tyr with lysosome-associated membrane protein 1 was observed within many of
these granules. Partial colocalization of Tyr with the Hermansky–Pudlak syndrome 1 gene product observed in
control melanocytes was abolished by TCA treatment. Our results show that these compounds decreased
intracellular melanin content by altering the trafficking of Tyr gene family proteins and inducing abnormal
secretion of Tyr. Results from our screening have implications for the design of products for skin lightening and
treatment of hyperpigmentation.
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INTRODUCTION
Skin and hair color are largely determined by the type and
amount of melanin synthesized by melanocytes within a
specialized organelle, the melanosome (Seiji et al., 1963;
Jimbow et al., 1976; Shen et al., 2001; Hearing, 2005). The
ability to modulate melanin synthesis, which in turn controls
skin and hair pigmentation, may be used to address a variety
of health-related conditions as well as cosmetic objectives.
Increasing skin pigmentation may protect the skin from the
deleterious effects of UV radiation. Decreasing pigmentation
is a desirable outcome in the treatment of skin diseases that
include acquired hyperpigmentation, such as melasma,
postinflammatory melanoderma, and solar lentigines (Cullen,
1998; Urabe et al., 1998).
Melanin is synthesized through a series of oxidative
reactions involving the amino-acid tyrosine. Tyrosinase
(Tyr), along with two Tyr-related proteins, Tyr-related protein
1 (Tyrp1) and 3,4-dihydroxyphenylalanine (DOPA) chrome
tautomerase/Tyr-related protein 2 (Dct/Tyrp2), form the enzy-
matic components of the melanosomes (Hearing, 2005). Tyr
is essential for the synthesis of melanin. It catalyzes the initial
and rate-limiting steps of melanogenesis (Korner and Pawe-
lek, 1982; Hearing, 1987; Tripathi et al., 1992). As Tyr plays a
central role in melanin synthesis, it is not surprising that many
previously identified pigmentation inhibitors act via effects
on this enzyme (Briganti et al., 2003; Kim and Uyama, 2005;
Parvez et al., 2006; Solano et al., 2006). Although a number
of whitening agents are commonly used for the treatment of
acquired skin hyperpigmentation, they are only modestly
active and some are known to produce adverse side effects
(Abramowitz and Chavin, 1980; Penney et al., 1984; Curto
et al., 1999). Therefore, there remains a need for compounds
that effectively modulate pigmentation.
Chemical genetics offers a powerful tool in the identifica-
tion of therapeutic candidates and their targets. A chemical
genetic approach has been successfully employed to identify
novel small molecules that control various biological
functions from compound collections or combinatorial
libraries (Tan, 2002; Schreiber, 2003; Khersonsky and Chang,
2004; Smukste and Stockwell, 2005; Zon and Peterson,
2005). We have identified novel compounds and their targets
involved in the regulation of mammalian pigmentation by
screening triazine-based combinatorial libraries that include
various linkers as intrinsic components of the small mole-
cules in the libraries (Williams et al., 2004; Jung et al., 2005;
Ni-Komatsu et al., 2005; Snyder et al., 2005; Ni-Komatsu and
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Orlow, 2007). In this study, we screened a commercially
available library of natural products and marketed drugs to
identify new pigmentation modulators. The rationale for
choosing this library is as follows: first, most of the
compounds in this library are known to be ‘‘bioactive’’ in
some way. Second, many compounds in the library have a
history of human use, which would therefore facilitate
clinical development. Third, after identification of a ‘‘hit’’
compound, additional compounds in the same class can be
tested, which provides useful information regarding struc-
ture–activity relationships. Finally, on the basis of known
function and mechanism of action of many of the library
compounds, one can readily test whether the previously
unreported functions of these molecules discovered by
screening are carried out by the same mechanism. The
screening was performed on immortalized murine melano-
cytes (melan-a cells) followed by melanin assay. Ten tricyclic
antidepressants (TCA) were identified that potently decreased
intracellular melanin content.
TCAs represent a class of agents first used in the 1950s
(Goodman and Gilman, 1996). They are named after the
drugs’ molecular structure, which contains three rings of
atoms. It is generally thought that TCAs work by inhibiting the
re-uptake of the neurotransmitters norepinephrine, dopa-
mine, and serotonin by nerve cells (Goodman and Gilman,
1996). All 10 TCAs tested in this study were found to potently
decrease intracellular melanin content, and the mechanism
by which they do so was further characterized and found to
involve disruption of the trafficking of Tyr and related
proteins.
RESULTS
Identification of tricyclic compounds that decreased
intracellular melanin content by screening the Spectrum
Collection library
A commercial library of 2,000 drugs and natural products
was screened to identify novel compounds that alter
intracellular melanin content in cultured murine melanocytes
(melan-a cells). Screening was performed at final compound
concentration of 1 mM in 24-well plates followed by melanin
assay. DMSO was used as a negative control and the Tyr
inhibitor phenylthiourea (PTU) was used as a positive control
on every plate (Hall and Orlow, 2005). Positive candidates
were rescreened in duplicate at final compound concentra-
tions of 1 and 5 mM, resulting in the identification of six TCAs
(amitriptyline hydrochloride, amoxapine, clomipramine hy-
drochloride, imipramine hydrochloride, nortriptyline hydro-
chloride, and trimipramine maleate) as compounds that
decreased intracellular melanin content.
These six compounds were purchased as pure chemicals
and were retested at final concentrations of 1, 2.5, and 5 mM
for their ability to decrease intracellular melanin content. As
all TCAs currently approved for use in the United States are
believed to function through the same mechanism, four other
TCAs that are commercially available as pure chemicals—
desipramine hydrochloride, doxepin hydrochloride, maproti-
line hydrochloride, and protriptyline hydrochloride—were
also tested under the same conditions for their ability to
decrease intracellular melanin content. All 10 TCAs tested
significantly decreased intracellular melanin content in a
dose-dependent manner in melan-a cells (Figure 1a). None of
the 10 TCAs showed any cytotoxicity at concentrations
below 10 mM (data not shown).
The IC50 values for decreasing intracellular melanin
content for the 10 TCAs were determined by culturing
melan-a cells with various concentrations of each compound
(Table 1). The dose–response curve of melan-a cells treated
with various concentrations of nortriptyline hydrochloride is
shown in Figure 1b (data not shown for the others).
Nortriptyline hydrochloride, amitriptyline hydrochloride,
trimipramine maleate, clomipramine hydrochloride, and
imipramine hydrochloride potently decreased intracellular
melanin content with IC50 values in the range of 1 mM,
whereas amoxapine, desipramine hydrochloride, doxepin
hydrochloride, protriptyline hydrochloride, and maprotiline
hydrochloride were less potent with IC50 values between 1
and 5 mM. The rank order of potency of the TCAs for
decreasing intracellular melanin content did not correlate
with their relative potency as antidepressants. For example,
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Figure 1. Effects of TCAs on intracellular melanin content in cultured
murine melanocytes. (a) Identification of tricyclic compounds that decreased
intracellular melanin content. Data are presented as the percentage of control,
and each column represents the mean±SD of multiple experiments. (b) The
dose–response curve of melan-a cells treated with various concentrations of
nortriptyline hydrochloride. Representative data from multiple experiments
are calculated with the Prism 5 program from Graphpad (San Diego, CA).
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whereas desipramine and doxepin are more potent anti-
depressants than imipramine (Goodman and Gilman, 1996),
imipramine is more potent in decreasing intracellular
melanin content (Table 1). In our system, the IC50 values of
two previously recognized pigmentation inhibitors, PTU and
hydroquinone, were 29 and 36 mM, respectively (Hall and
Orlow, 2005). These data suggest that all 10 TCAs tested in
this study are more potent in decreasing intracellular melanin
content than most currently available depigmenting com-
pounds.
To gain insight into structure–activity relationships, addi-
tional compounds that share structural similarity to TCAs
were tested for their ability to alter intracellular melanin
content in melan-a cells (Table 2). The data suggest that a
Table 1. Structures of the tricyclic antidepressants that decrease intracellular melanin content and their IC50 values
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compound with a tertiary amine side chain attached to the
center ring seems to be more potent than a compound that
has a secondary amine side chain attached. For example,
imipramine hydrochloride, having an N,N-dimethylpropyla-
mine side chain attached to the center azepane ring, showed
an IC50 value of 0.76mM, approximately fourfold more potent
than its close analogue desipramine hydrochloride, a mole-
cule that bears an N-methylpropylamine side chain (Table 1).
Interestingly, alterations in the size of the middle ring are well
tolerated. In fact, even analogues with the center ring
opened, but structurally matched to the TCA pharmacophore,
showed good activity. For example, orphenadrine hydro-
chloride and tripelennamine hydrochloride were found to be
active inhibitors, with approximately 40–60% inhibition at
5 mM (Table 2). Furthermore, additions of heteroatoms to the
middle ring are well tolerated without affecting activity.
Effects of tricyclic compounds on Tyr activity
Tyr plays a key role in melanogenesis and many depigment-
ing compounds act via effects on the expression, processing,
maturation, degradation, and enzymatic activity of Tyr
(Briganti et al., 2003; Kim and Uyama, 2005; Parvez et al.,
Table 2. Compounds with structures similar to tricyclic antidepressants and their effects on intracellular melanin
content in melan-a cells
www.jidonline.org 1239
L Ni-Komatsu and SJ Orlow
Compounds Alter Tyrosinase Trafficking
2006; Solano et al., 2006). Therefore, we performed several
assays to determine whether the TCAs affected Tyr enzymatic
activity.
The effect of TCAs on Tyr activity was studied both in vitro
using melan-a cell lysates and in living melan-a cells. None
of the 10 TCAs directly inhibited Tyr enzymatic activity in the
melan-a cell extracts (data not shown). Tyramide-based Tyr
assay (TTA assay) (Han et al., 2002), an in situ Tyr activity
assay, was performed to detect Tyr activity in living melan-a
cells (Figure 2). Tyr-related albino melanocytes (melan-c
cells) and PTU-treated melan-a cells were used as negative
and positive controls, respectively (Figure 2). Clomipramine,
imipramine, nortriptyline, protriptyline, trimipramine (Fig-
ure 2), and the other five TCAs (data not shown) had no
significant effect on Tyr activity in melan-a cells. These data
suggested that none of the TCAs decreased intracellular
melanin content through direct Tyr inhibition. However, TTA
assay data indicated that the subcellular localization of Tyr
might be altered in the melan-a cells treated with TCAs
(Figure 2).
The TCAs did not appear to alter levels of Tyr, Tyrp1, or
Dct proteins (data not shown). Endoglycosidase H
digestion data suggested that there was no obvious
change in the endoglycosidase H sensitivity of Tyr after
melan-a cells were treated with these compounds (data not
shown).
Tricyclic compounds cause increased secretion of Tyr and
increased extracellular melanin
The presence of melanin in the extracellular culture media
has been previously reported in both oculocutaneous
albinism (OCA) type 2 and type 4 melanocytes (Potterf
et al., 1998; Costin et al., 2003). In melan-p melanocytes
cultured from OCA2 mice, active Tyr and soluble melanin
are secreted into the media; whereas in OCA4 melanocytes,
Tyr is secreted from the cells within vesicles, and the melanin
produced in these vesicles is readily sedimented by
centrifugation.
We noted that the color of the extracellular culture media
of TCA-treated melan-a cells was significantly darker than
that of the untreated melan-a cells (Figure 3a), suggesting that
treatment with TCAs increased the presence of melanin in the
culture media. The melanin present in the media could not be
sedimented by 30-minute centrifugation at 14,000 r.p.m.
Untreated Melan-c PTU Clomipramine
TrimipramineImipramine ProtriptylineNortriptyline
Figure 2. Effects of tricyclic compounds on Tyr activity in living melan-a cells. TTA assay was performed and Tyr activity is shown in red. Melan-c cells,
cultured from albino mice with a defect in the Tyr gene, were used as negative control. PTU, a known Tyr inhibitor, was used as positive control. Bars¼ 5 mm.
Un
tre
at
ed
N
or
tri
pt
yli
ne
Am
itr
ip
ty
lin
e
Pr
ot
rip
ty
lin
e
Cl
om
ip
ra
m
in
e
Am
ox
a
pi
ne
Im
ip
ra
m
in
e
D
es
ip
ra
m
in
e
Un
tre
at
ed
N
or
tri
pt
yli
ne
Am
itr
ip
ty
lin
e
Pr
ot
rip
ty
lin
e
Cl
om
ip
ra
m
in
e
Am
ox
a
pi
ne
Im
ip
ra
m
in
e
D
es
ip
ra
m
in
e
Un
tre
at
ed
N
or
tri
pt
yli
ne
Am
itr
ip
ty
lin
e
Pr
ot
rip
ty
lin
e
Cl
om
ip
ra
m
in
e
Am
ox
a
pi
ne
Im
ip
ra
m
in
e
D
es
ip
ra
m
in
e
97k
66k
97k
66k
1.0 2.5 2.6 1.6 2.1 2.3 2.32.9
Figure 3. Increased presence of both Tyr and melanin in the culture media
of melan-a cells treated with tricyclic compounds. (a) Melanin in the
extracellular culture media of TCA-treated melan-a cells. (b) DOPA oxidase
activity of Tyr in melan-a cells lysates with or without TCAs treatment.
(c) DOPA oxidase activity of Tyr in the extracellular media of melan-a
cells with or without TCAs treatment. The fold increase in Tyr activity is
shown at the bottom of the gel.
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(data not shown), suggesting that it is of low molecular
weight.
DOPA oxidase activity of Tyr was measured in both cell
lysates and the extracellular culture media by staining
samples with L-DOPA (L-3,4-dihydroxyphenylalanine) and
MBTH (3-methyl-2-benzothiazolinone hydrozone) on non-
denaturing polyacrylamide gels. TCA treatment did not
obviously affect the Tyr activity in the cell lysates (Figure
3b), consistent with the TTA assay results (Figure 2), and
further confirmed that none of the TCAs acted as direct
inhibitors of Tyr. By contrast, with TCA treatment a 1.6- to
2.9-fold increase in Tyr activity was observed in the
extracellular culture media (Figure 3c). These results sug-
gested that TCA treatment increased the secretion of active
Tyr into the culture media, which could explain in whole or
in part the increased presence of melanin in the extracellular
culture media.
Alterations of the Subcellular Distributions of Tyr Gene Family
Proteins by TCAs
Tyr and the related proteins, Tyr-related protein 1 and
dopachrome tautomerase/Tyr-related protein 2, are melano-
cyte-specific enzymes involved in melanin synthesis. Many
disorders of hypopigmentation are due to alterations in the
subcellular distribution of these proteins (Chen et al., 2002;
Spritz et al., 2003; Richmond et al., 2005; Wei, 2006).
Therefore, compounds that decrease pigmentation could act
through altering the subcellular distribution of these proteins,
a phenomenon reported previously by our laboratory (Hall
et al., 2003).
The subcellular localizations of the Tyr gene family
proteins, Tyr, Tyrp1, and Dct (data not shown), in melan-a
cells treated with TCAs were evaluated by immunofluores-
cence (Figure 4). As observed previously in these cells (Chen
et al., 2002; Toyofuku et al., 2002), in the vehicle-treated
melan-a cells, Tyr, Tyrp1, and Dct (data not shown) were
found in granules distributed throughout the cytoplasm, as
well as in the perinuclear area where the endoplasmic
reticulum, Golgi, and stage I melanosomes are located.
Dramatic differences in the subcellular distribution of
the Tyr gene family proteins were observed after treatment
of melan-a cells with TCAs. In the TCA-treated cells,
all three proteins (data not shown for Dct) were localized to
enlarged granules distributed throughout the cytoplasm
(Figure 4).
Induction of Tyr and lysosome-associated membrane protein 1
colocalization by TCAs
The distribution pattern of Tyr gene family proteins in the
TCA-treated melan-a cells was strikingly similar to what has
been observed in human melanocytes cultured from patients
with Hermansky–Pudlak Syndrome (HPS) subtype 1 (HPS1)
(Richmond et al., 2005). In HPS1 melanocytes, in addition to
Tyr gene family proteins, lysosome-associated membrane
protein 1 (Lamp-1) is also localized to abnormal large
granules. Therefore, the subcellular localization of Lamp-1
in the TCA-treated melan-a cells was investigated by
immunofluorescence.
In control melan-a cells, Lamp-1 was mainly localized in
cytoplasmic granules with some in the perinuclear area
(Figure 5a). No obvious colocalization of Lamp-1 with Tyr
was observed in untreated melan-a cells, consistent with a
previous report that Tyr is not detected in late endosomes/
lysosomes in these cells (Hall et al., 2003). By contrast, in the
nortriptyline- or protriptyline-treated melan-a cells, Lamp-1
was localized to enlarged vesicles similar to that observed for
the Tyr gene family proteins (Figure 5a). In addition, an
increased colocalization of Tyr and Lamp-1 was also
observed in the cells treated with these two compounds for
72 hours (Figure 5a). Quantitative analysis was performed on
20–25 of either vehicle- or TCAs-treated cells, and the results
indicated a 4.7 (Po0.002)- and 3.4 (Po0.001)-fold increase
in the colocalization of Tyr and Lamp-1 in cells treated with
nortriptyline or protriptyline, respectively, compared to the
vehicle-treated cells. Similar results were observed in the
melan-a cells treated with each of the other eight TCAs (data
not shown).
The similarities between HPS1 melanocytes and TCA-
treated melan-a cells led us to examine the colocalization of
HPS1 with Tyr in TCA-treated cells. pCR3.1/myc-HPS1, a
plasmid that expresses full-length human HPS1 protein with
the Myc epitope at the N terminus, was transiently transfected
into melan-a cells. The transfected cells were treated with
either nortriptyline or protriptyline, and the subcellular
localization of HPS1 and Tyr in these cells was investigated
by immunofluorescence. In untreated control cells, HPS1
showed a distinct perinuclear pattern, which overlapped in
part with that of Tyr (Figure 5b). In nortriptyline- and
protriptyline-treated cells, the partial colocalization of HPS1
with Tyr was abolished due to the alteration in Tyr trafficking
(Figure 5b).
DISCUSSION
Our laboratory has successfully demonstrated that chemical
genetic screening is a powerful tool in identifying novel
compounds and their targets involved in the regulation of
mammalian pigmentation (Williams et al., 2004; Jung et al.,
2005; Ni-Komatsu et al., 2005; Snyder et al., 2005; Ni-
Komatsu and Orlow, 2007). In this study, we screened the
commercially available Spectrum Collection, a library of
natural products and marketed drugs, to identify new
pigmentation modulators.
By screening the Spectrum Collection, we have identified
a group of 10 TCAs that potently decreased intracellular
melanin content. Screening was performed in cultured
melan-a cells followed by quantitative melanin assay to
identify compounds that alter pigmentation. Further char-
acterization of these tricyclic compounds suggested that they
decreased intracellular melanin content through altering the
intracellular trafficking of Tyr gene family proteins and
inducing the abnormal secretion of Tyr into the extracellular
culture media.
Although the exact mechanism of action is not well
understood, it is generally believed that TCAs treat depression
by inhibiting the re-uptake of neurotransmitters such as
serotonin and norepinephrine by nerve cells (Goodman and
www.jidonline.org 1241
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Gilman, 1996). Previous studies have suggested a presump-
tive role of serotonin in melanogenesis (Slominski et al.,
2004, 2005). In SK-MEL 188 human melanoma cells,
serotonin inhibited DMEM-induced melanogenesis in a
dose-dependent manner (Slominski et al., 2004). Other
studies have shown that certain serotonin-uptake inhibitors
inhibited melanization in human melanoma cells (McEwan
and Parsons, 1987). However, our results indicated that TCAs
decreased intracellular melanin content in melan-a cells
through mechanisms other than affecting serotonin re-uptake.
There was no correspondence between the activities of these
TCAs as antidepressants and their rank-order activities in
decreasing intracellular melanin content. For example,
although the effective concentrations of desipramine and
doxepin as antidepressants are lower than that of imipramine
(Goodman and Gilman, 1996), imipramine was the more
effective one at decreasing intracellular melanin content
(Table 1). Moreover, adding extra serotonin at final concen-
tration up to 100 mM (100-fold greater than the TCA
concentration) to the cell culture media could not rescue
the reduction in intracellular melanin content in TCA-treated
melan-a cells (data not shown). Thus, these compounds
decrease melanin content through a mechanism different
than their action as antidepressants.
The activity of at least three enzymes, Tyr, Tyrp1, and Dct,
is required for normal melanin synthesis, with Tyr controlling
the key rate-limiting steps (Hearing, 2005). After synthesis in
the rough endoplasmic reticulum, these proteins traffic to the
Tyr Tyrp1 Merge
Untreated
Clomipramine
Imipramine
Nortriptyline
Protriptyline
Trimipramine
Figure 4. Alterations of the subcellular localization of Tyr and Tyrp1 by tricyclic compounds. Immunofluorescence confocal microscopy images are shown
with immunostaining of Tyr (green) and Tyrp1 (red). Colocalization of Tyr with Tyrp1 is indicated in yellow in the merge. Bars¼5 mm.
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Golgi network where glycosylation and post-translational
modifications take place. They are then sorted through trans-
Golgi network, early endosomes, and late endosomes by
secretory vesicles and finally reach their intended destina-
tion, the melanosomes, where the synthesis of melanin
begins. A simple model of Tyr trafficking in melanocytes is
presented in Figure 6. Alterations in the subcellular distribu-
tion of these proteins contribute to many genetic disorders of
0 hour
24 hours
48 hours
72 hours
96 hours
Nortriptyline Protriptyline
Tyr Lamp-1 Merge Tyr Lamp-1 Merge
Tyr myc-HPS1 Merge
Untreated
Untreated
Nortriptyline
Protriptyline
Figure 5. Effects of tricyclic compounds on the colocalization of Tyr with either lysosome-associated membrane protein 1 (Lamp-1) or HPS1. (a) TCAs
induced partial colocalization of Tyr and Lamp-1. Immunoflurescence confocal microscopy images are shown with immunostaining of Tyr (red) and Lamp-1
(green). The colocalization of Tyr with Lamp-1 is indicated in yellow in the merge. (b) TCAs abolished the partial colocalization of HPS1 with Tyr.
Immunofluorescence confocal microscopy images are shown with immunostaining of Tyr (red) and myc-HPS1 (green). The colocalization of Tyr with HPS1 is
indicated in yellow in the merge. Bars¼ 5 mm.
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hypopigmentation, such as the group of multisystem dis-
orders classified as HPS (Chen et al., 2002; Spritz et al., 2003;
Richmond et al., 2005; Wei, 2006). It has been reported that
in the absence of HPS1, both the Tyr gene family proteins and
Lamp-1 are sequestered into enlarged vesicles (Boissy et al.,
1998). The striking similarity between HPS1 melanocytes and
TCA-treated melan-a cells leads us to propose that TCAs
decrease intracellular melanin content by targeting the same
pathway controlled by HPS1 (Figure 6).
Although melan-a cells treated with TCAs expressed
normal levels of Tyr protein and enzymatic activity, our data
indicate that TCAs disrupt the intracellular trafficking of Tyr
gene family proteins. The majority of these proteins are
trapped in enlarged vesicles throughout the cytoplasm in
TCA-treated cells. The mislocalization of these proteins most
likely induces the secretion of a significant amount of Tyr into
the extracellular culture medium, contributing to the in-
creased presence of melanin in the extracellular culture
media. However, it is difficult to confirm whether there is
also an increase in the secretion of melanin itself in the TCA-
treated cells. It has been previously reported that certain
TCAs can alter intracellular protein and lipid trafficking
(Honegger et al., 1983; Toplak et al., 1990; Roff et al., 1991;
Palmeri et al., 1992; Hurwitz et al., 1994; Sato et al., 1998;
Bu¨rgi et al., 2003; Kolzer et al., 2004). For example,
imipramine induces lysosomal accumulation of cholesterol
by blocking the postlysosomal transport of cholesterol (Roff
et al., 1991; Palmeri et al., 1992; Sato et al., 1998). Honegger
et al. have reported that chronic desipramine exposure results
in alteration of the cellular and membranous phospholipid
patterns (Toplak et al., 1990) and promotes lysosomal
phospholipid accumulation (Honegger et al., 1983). The
same group later reported that chronic exposure to desipra-
mine also impairs b1-adrenoceptor recycling in rat C6 glio-
blastoma cells through a modulation of receptor trafficking
pathways (Bu¨rgi et al., 2003). Sandhoff et al. have demon-
strated that imipramine and amitriptyline can induce the
release of acid sphingomyelinase from the cellular membrane
into the vesicular space, which results in proteolytic
degradation of the enzyme in intracellular vesicles (Hurwitz
et al., 1994; Sato et al., 1998; Kolzer et al., 2004). Previous
data from our laboratory also suggest a role of imipramine in
altering late endosomal/lysosomal trafficking (unpublished
data).
It is not surprising that TCA treatment altered the
trafficking of both Tyr gene family proteins and Lamp-1. A
common lineage among melanosomes and lysosomes is well
accepted (Diment et al., 1995; Orlow, 1995; Marks and
Seabra, 2001; Raposo and Marks, 2002; Dell’Angelica,
2003). Both organelles contain certain proteins in common,
and both are affected in several single gene disorders (Zhao
et al., 1994; Boissy et al., 1998; Marks and Seabra, 2001).
Many studies have shown that Tyr is localized to the
lysosomal compartments when expressed in non-melanocy-
tic cells, where its intended destination, the melanosome,
does not exist (Winder, 1991; Winder et al., 1993a; Toyofuku
et al., 1999; Berson et al., 2000; Ni-Komatsu and Orlow,
2006). Additional evidence to support this proposal is that
when Tyrp1 is expressed in fibroblasts, it too is located in late
endosomes and lysosomes (Winder et al., 1993b).
Doxepin has been studied as a topical cream for its effects
on a variety of conditions including pruritus and pain (Drake
and Millikan, 1995; Drake et al., 1999; McCleane, 2000).
These studies were of limited duration, most being only 7
days in length, with the longest application period being 4
weeks (McCleane, 2000). Diminished cutaneous pigmenta-
tion has not been noted in these studies. However, it was
neither an end point that was being examined nor a side
effect that would have been expected. Typically, topical
agents intended to diminish cutaneous pigmentation are
Early
endosome
Cell membrane
Tyr
Tyr
Tyr
Tyr
Tyr
Tyr
TCAs
Late
endosome
ER
cis-Golgi
trans-Golgi network
HPS1
HPS1
AP3
AP3
AP3
Stage IV
Stage III
Stage II
Stage I
Figure 6. The proposed roles played by the newly identified tricyclic compounds in the regulation of Tyr trafficking in melanocytes. TCAs may decrease
intracellular melanin content by targeting the same pathway controlled by HPS1.
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studied for longer periods of time and in conditions such as
solar lentigines where pigment production is highest.
Although doxepin’s ability to penetrate the epidermis when
applied topically is substantial (Drake et al., 1999), its
duration in epidermis, let alone in melanocytes, has not been
examined.
Orally administered TCAs may on rare occasion be
associated with dermal blue-gray pigmentation in sun-
exposed areas (Sicari et al., 1999; Metelitsa et al., 2005).
This pigmentation may result from the deposition of melanin
in an unusual form. The melanin pigment is possibly
complexed with a metabolite of imipramine and does not
represent the deposition of imipramine in its native form
(Ming et al., 1999). Desipramine and imipramine are most
associated with this complication. In the case of the best
studied topical TCA, doxepin, this effect has not been noted,
so its clinical relevance is unclear.
Our results further extend the use of a chemical genetic
approach to dissect the mammalian pigmentation pathway,
and identify, to our knowledge, a previously unreported
group of compounds that decrease intracellular melanin
content, which may prove useful in further elucidating
pathways controlling melanosomal trafficking. These also
give insight into structure–activity relationship of compounds
that decrease intracellular melanin content and thus may
provide potential active agents and targets for the medical
and aesthetic treatment of disorders of pigmentation.
MATERIALS AND METHODS
Reagents and antibodies
All the TCAs and structurally related compounds used in this study
(amitriptyline hydrochloride, amoxapine, clomipramine hydrochlor-
ide, desipramine hydrochloride, doxepin hydrochloride, imipramine
hydrochloride, maprotiline hydrochloride, nortriptyline hydrochlor-
ide, protriptyline hydrochloride, trimipramine maleate, chlorprothix-
ene hydrochloride, clozapine, cyclobenzaprine hydrochloride,
cyproheptadine hydrochloride, dizocilpine MK801 hydrogen mal-
eate, loxapine succinate, orphenadrine hydrochloride, promazine
hydrochloride, promethazine hydrochloride, and tripelennamine
hydrochloride), and L-DOPA and MBTH were purchased from
Sigma-Aldrich (St Louis, MO).
aPep7 antiserum was raised against the C terminus of mouse Tyr
based on reported antigenic peptide sequences (Jimenez et al.,
1991). The following antibodies were also used: Mel-5, a mAb
reactive with mouse Tyrp1 (Signet Laboratories Inc., Dedham, MA);
1D4B, a mAb reactive with mouse Lamp-1 (The Developmental
Studies Hybridoma Bank, Iowa city, IA); 9E10, a mAb reactive with
c-Myc (Sigma-Aldrich).
Compound library
The library used in this study was The Spectrum Collection
(MicroSource Discovery Inc., Gaylordsville, CT). The 2,000 com-
pounds in this library are either marketed drugs or natural products,
supplied as 10mM solution in DMSO.
Cell culture
Murine melan-a and melan-c cells were cultured as reported
previously (Chen et al., 2002).
Screening of the compound library in melan-a cells
Melan-a cells were plated at 5 104 cells per well in 1ml of culture
media in 24-well plates the day before adding the library
compounds. All compounds were added at the indicated final
concentrations. For all the experiments, DMSO was used as a
negative control and the well-known pigmentation inhibitor PTU
was used as a positive control (Hall and Orlow, 2005). Cells were
harvested after 72 hours of incubation unless otherwise noted, and
melanin assay was performed. Cell viability was determined by
using the CellTiter 96 aqueous nonradioactive cell proliferation
assay (Promega, Madison, WI).
Melanin assay
Melanin assay was performed as reported previously (Ni-Komatsu
et al., 2005).
TTA assay
TTA assay, an in situ Tyr activity assay, was performed as reported
previously (Han et al., 2002). Briefly, cells were cultured on
coverslips (Fisher Scientific, Pittsburgh, PA), incubated with or
without 5 mM TCAs for 72 hours at 37 1C. Melan-c cells, which
express an inactive Tyr, were used as negative control, and PTU-
treated melan-a cells were used as positive control. The samples
were analyzed with a confocal microscope (LSM 510; Zeiss, Proctor,
MN).
DOPA staining on non-denaturing polyacrylamide gel
DOPA oxidase activity of Tyr was assessed as reported previously
(Jimenez-Cervantes et al., 1993) by staining samples with L-DOPA
and MBTH on non-denaturing polyacrylamide gels. Briefly, samples
were mixed with loading buffer without reducing agents, SDS or
boiling. Gels were washed with 50mM pH 6.0 phosphate buffer and
then incubated in 10mM pH 6.8 phosphate buffer containing 4mM
MBTH and 1.5mM L-DOPA.
Plasmid and transfection
pCR3.1/myc-HPS1, a plasmid that expresses full-length human HPS1
protein with the Myc epitope at the N terminus, was a generous gift
from Dr Esteban C. Dell’Angelica (Department of Human Genetics,
David Geffen School of Medicine, University of California, Los
Angeles, CA). pCR3.1/myc-HPS1 was transiently transfected into
melan-a cells with Cell Line Nucleofector Kit L (Amaxa, Gaithers-
burg, MD) according to the manufacturer’s instructions. After
overnight incubation, nortriptyline hydrochloride or protriptyline
hydrochloride was added to transfected cells at the final concentra-
tion of 5mM. Cells were cultured for an additional 72 hours and
immunofluorescence analysis was performed.
Immunofluorescence microscopy
Cells were cultured on coverslips (Fisher Scientific), incubated with
or without 5mM TCAs for 72 hours or the indicated time at 37 1C.
Cells were fixed with 20 1C methanol for 5minutes and stained as
described previously (Shen et al., 2001). Slides were analyzed with a
confocal microscope (LSM 510; Zeiss).
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